This title slide, titled "CIN Screening & Management," presents a comprehensive academic review tailored for final year MBBS students. Its subtitle emphasizes a deep dive into CIN screening, evaluation, and management.

A Comprehensive Academic Review

for Final Year MBBS

CIN Screening, Evaluation & Management Deep Dive

Source: PowerPoint Enhancement: Modern Academic Theme

The presentation agenda covers CIN Basics Overview, Screening Methods & Techniques, CIN Evaluation & Grading, Management Algorithms, and Prevention Strategies. Each item includes a focused description on topics like etiology, HPV testing, colposcopy, treatment pathways, and vaccination.

Presentation Agenda

1. CIN Basics Overview

Foundational knowledge on Cervical Intraepithelial Neoplasia etiology and epidemiology.

2. Screening Methods & Techniques

Pap smear, HPV testing, and WHO-aligned screening protocols.

3. CIN Evaluation & Grading

Colposcopy, biopsy techniques, and histopathological CIN grading systems.

4. Management Algorithms

Evidence-based treatment pathways and FOGSI-recommended algorithms.

5. Prevention Strategies

HPV vaccination, early detection, and public health prevention measures. Source: CIN Screening, Evaluation & Management Deep Dive

This section header slide introduces "CIN Basics" as section 02 of the presentation. It focuses on the fundamentals of Cervical Intraepithelial Neoplasia and the WHO classification.

CIN: Cervical Intraepithelial Neoplasia Basics

02

CIN Basics

Understanding Cervical Intraepithelial Neoplasia Fundamentals and WHO Classification

Source: WHO-aligned intro visual with teal gradient and purple accents

CIN grading categorizes cervical intraepithelial neoplasia as CIN 1 (mild dysplasia, lower regression risk), CIN 2 (moderate dysplasia, higher progression potential), and CIN 3 (severe dysplasia/CIS, elevated cancer risk). High-risk HPV types (16, 18) drive progression, with risk factors like smoking and immunosuppression accelerating the disease.

CIN Grading & Risk Factors

• CIN 1: Mild dysplasia, lower regression risk
• CIN 2: Moderate dysplasia, higher progression potential
• CIN 3: Severe dysplasia/CIS, elevated cancer risk
• High-risk HPV types (16,18) drive CIN progression
• Risk factors: Smoking, immunosuppression accelerate disease

Source: CIN Screening, Evaluation & Management Deep Dive

The slide outlines Pap smear technique in three steps: position patient in lithotomy and insert speculum, visualize cervix and collect ectoendocervical sample, then use broom/spatula to transfer to slide/vial. It also notes HPV vaccination with Gardasil-9 at 0, 2, 6 months per WHO guidelines.

Pap Smear Technique & HPV Vaccination

!Image

• Step 1: Position patient in lithotomy; insert speculum.
• Step 2: Visualize cervix; collect ectoendocervical sample.
• Step 3: Use broom/spatula; transfer to slide/vial.
• HPV Vaccine: Gardasil-9 at 0,2,6 months (WHO).

Source: Infographic: Step-by-step Pap smear collection + HPV vaccine schedule (Gardasil-9, WHO/FOGSI recs)

The CIN Screening & Evaluation Algorithm per FOGSI Guidelines outlines a step-wise workflow starting with Pap smear results: normal smears repeat in 3 years, ASCUS requires HPV testing (colposcopy if positive), and LSIL/HSIL lead to immediate colposcopy. Colposcopy involves acetic acid inspection and biopsy of suspicious areas, followed by histological grading (CIN1/2/3) to guide treatments like LEEP or cone biopsy.

CIN Screening & Evaluation Algorithm (FOGSI Guidelines)

Source: FOGSI & WHO Aligned

CIN Management Strategies table outlines treatments and follow-ups by grade: CIN1 is managed with observation and repeat Pap in 6-12 months. CIN2 and CIN3 both use LEEP/Cone, with colposcopy post-procedure for CIN2 and histology confirmation for CIN3.

CIN Management Strategies

Source: WHO & FOGSI Guidelines

Implement routine HPV vaccination, Pap smear screening, and early CIN detection via colposcopy, while following WHO/FOGSI guidelines for grading and management. Prevention focuses on vaccinate, screen, treat early; contacts provided, with a call to stay vigilant, save lives, and discuss questions.

Key Takeaways & Q&A

<ul style='font-size: 24px; line-height: 1.4;'> <li>Implement routine HPV vaccination & Pap smear screening</li> <li>Early CIN detection via colposcopy improves outcomes</li> <li>Follow WHO/FOGSI guidelines for grading & management</li> <li>Prevention: Vaccinate, Screen, Treat early</li> <li>Contacts: [Your Clinic/Hospital] | WHO Guidelines | FOGSI Hotline</li> </ul> <div style='margin-top: 20px; font-size: 28px; font-weight: bold; color: teal;'>Stay Vigilant, Save Lives</div> <div style='margin-top: 10px; font-size: 20px;'>Questions? Let's Discuss!</div>

Thank You

Source: CIN Screening, Evaluation & Management Deep Dive